188 results on '"de Boer NK"'
Search Results
2. Safety of a (H1N1)V Vaccine in patients with inflammatory bowel disease treated with immunomodulators and biologicals
- Author
-
Rahier, J. F., Papay, P, Salleron, J, Sebastian, S, Marzo, M, Peyrin Biroulet, L, Garcia, V, Fries, Walter, van Asseldonk FP, Farkas, K, de Boer NK, Sipponen, T, Ellul, P, Louis, E, Peake, S, Kopylov, U, Maul, J, Makhoul, B, Fiorino, Gionata, Yazdanpanah, Y, Chaparro, M, for the European Crohn’s, and Colitis, Organization
- Published
- 2010
3. MRC OX19 RECOGNIZES THE RAT CD5 SURFACE GLYCOPROTEIN, BUT DOES NOT PROVIDE EVIDENCE FOR THE PRESENCE OF A DISTINCT CD5 POSITIVE B CELL POPULATION IN THE RAT
- Author
-
VERMEER LA, DE BOER NK, BOS NA, KROESE FG, ALBERTI S., BUCCI, Cecilia, Vermeer, La, DE BOER, Nk, Bucci, Cecilia, Bos, Na, Kroese, Fg, and Alberti, S.
- Subjects
immune system diseases ,hemic and lymphatic diseases - Abstract
To clone the rat CD5 gene we first produced two rat CD5 probes. The probes were obtained by polymerase chain reaction (PCR) on rat genomic DNA using primers designed on conserved regions between mouse and human CD5. The screening of a rat cDNA library at high stringency using these probes resulted in a 1.5-kb positive clone. The DNA sequence of this clone confirmed its CD5 nature, but the clone appeared to lack part of the 5' and part of the 3' end. These missing 5' and 3' ends were obtained by PCR on rat thymus RNA. By ligating these PCR products to the original 1.5-kb CDM8 clone, a full-length rat CD5 gene was constructed. The full-length clone showed high identity with mouse and human CD5; however, at the 5' site of the gene a region of 36 nucleotides is present which is not seen in either mouse or human CD5. We have evidence that this sequence is a normal constituent of the rat CD5 gene: first, it is in frame with the rest of the CD5 coding sequence; second, it does not contain a stop codon; and third, it is also present in the CD5 gene of other rat strains. We transfected the full-length CD5 construct in COS cells and demonstrated that indeed the CD5 protein is recognized by MRC OX19. Although we showed that CD5 mRNA is present in rat B cells, extensive flow cytometry analysis using MRC OX19 as antibody failed to detect B cells expressing significant levels of CD5 on their cell surface compared to other B cells in any tissue or cell suspension tested from a variety of rat strains. This is in contrast with the mouse where a distinct population of B cells (B-1a cells) can be found expressing more CD5 than the other B cells. Either B-1 cells are not present in rats or CD5 is not the right phenotypic marker for rat B-1 cells. It still remains to be investigated whether a population of B cells with functions similar to those of murine B-1 cells is present in rats.
- Published
- 1994
4. Nonsteroidal Anti-Inflammatory Drug Associated Colopathy
- Author
-
Van Weyenberg, SJB, primary and de Boer, NK, additional
- Published
- 2013
- Full Text
- View/download PDF
5. Enterobiasis vermicularis
- Author
-
Van Weyenberg, SJB, primary and De Boer, NK, additional
- Published
- 2013
- Full Text
- View/download PDF
6. Reply
- Author
-
Seinen Ml, van Bodegraven Aa, and De Boer Nk
- Subjects
World Wide Web ,Text mining ,Hepatology ,business.industry ,Gastroenterology ,Medicine ,business - Published
- 2013
7. Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in Crohn's disease.
- Author
-
de Boer NK, Derijks LJ, Keizer-Garritsen JJ, Lambooy LH, Ruitenbeek W, Hooymans PM, van Bodegraven AA, and de Jong DJ
- Abstract
The proposed metabolic advantage of 6-thioguanine (6-TG) is the direct conversion into the pharmacologically active 6-thioguaninenucleotides (6-TGN). The authors assessed metabolic characteristics of 6-TG treatment in patients with Crohn's disease (N = 7) on therapy with 20 mg 6-TG. 6-thioguanine-monophosphate (6-TGMP), 6-thioguanine-diphosphate (6-TGDP), and 6-thioguanine-triphosphate (6-TGTP) were measured by high-performance liquid chromatography analysis in erythrocytes. Thiopurine S-methyltransferase activity and total 6-TGN levels were determined by standard methods. High interindividual variance in metabolite measurements was observed. Main metabolites were 6-TGTP (median = 531 pmol/8 x 10(8) red blood cells) and 6-TGDP (median = 199 pmol/8 x 10(8) red blood cells). Traces of 6-TGMP (median = 39 pmol/8 x 10(8) red blood cells) and 6-TG (2 patients) could be detected. 6-TGN levels correlated with 6-TGTP levels (r = 0.929, P = .003) and with the sum of separate nucleotides (r = 0.929, P = .003). No correlations were established between TPMT activity (median = 13 pmol/h/10(7)) and 6-TG metabolites. The 1-step metabolism of 6-TG still leads to high interindividual variance in metabolite concentrations. Total 6-TGN level monitoring may suffice for clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
8. Management of Crohn's disease in poor responders to adalimumab
- Author
-
de Boer NKH, Löwenberg M, and Hoentjen F
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Nanne KH de Boer,1 Mark Löwenberg,2 Frank Hoentjen3 1Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands; 2Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands; 3Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands Abstract: Anti-tumor necrosis factor therapy with adalimumab is an effective therapy for the induction and maintenance of remission in moderate to severe Crohn's disease. Although a large proportion of patients show a favorable clinical response to adalimumab, therapy failure is common. In this review, we provide a practical overview of adalimumab therapy in patients with Crohn's disease, with a specific focus on the clinical management of adalimumab failure. In the case of inadequate efficacy, a thorough assessment is required to confirm inflammatory disease activity and rule out noninflammatory causes. Evaluation may include biomarkers (fecal calprotectin and serum C-reactive protein), colonoscopy, and/or magnetic resonance enterography/enteroclysis. Furthermore, adalimumab trough levels and antibodies to adalimumab are informational after the confirmation of active inflammation. In the case of low or undetectable adalimumab trough levels, dose escalation to 40 mg weekly is recommended, whereas high antibody titers or adverse events frequently require switching to an alternative anti-TNF agent such as infliximab. Active inflammation despite therapeutic adalimumab trough levels requires alternative strategies such as switching to drugs with a different mode of action or surgical intervention. Keywords: anti-TNF, biological, inflammatory bowel disease, loss of response, infliximab
- Published
- 2014
9. Golimumab for the treatment of ulcerative colitis
- Author
-
Löwenberg M, de Boer NKH, and Hoentjen F
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Mark Löwenberg,1 Nanne KH de Boer,2 Frank Hoentjen3 1Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands; 2Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, the Netherlands; 3Inflammatory Bowel Disease Center, Radboud University Medical Center, Nijmegen, the Netherlands Abstract: The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in UC and have an acceptable safety profile. However, a proportion of UC patients for whom therapy with anti-TNF agents is indicated fail or become intolerant to treatment with infliximab or adalimumab. Hence, there remains an unmet need for novel anti-TNF agents. Golimumab (Simponi®), a human anti-TNF antibody that is administered by monthly subcutaneous injections, is the most recently introduced TNF blocker for the treatment of UC. Here, we will discuss recent literature on clinical efficacy and safety of golimumab induction and maintenance treatment in patients with UC. Furthermore, we will discuss the positioning of golimumab for UC in current treatment algorithms. Keywords: ulcerative colitis, UC, antitumor necrosis factor, TNF, antibodies, golimumab
- Published
- 2014
10. A sarcoid-like reaction in a patient with hemangiopericytoma: mediastinal lymphadenopathy resulting in confusion about therapy.
- Author
-
van Hoesel AQ, Hoekstra HJ, de Boer NK, Jager PL, and van der Graaf WTA
- Published
- 2003
- Full Text
- View/download PDF
11. Rectal Meckel's diverticulum.
- Author
-
de Boer NK and Kuyvenhoven JP
- Published
- 2009
- Full Text
- View/download PDF
12. The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naïve Inflammatory Bowel Disease Patients.
- Author
-
Crouwel F, Bayoumy AB, Mulder CJJ, Peters JHC, Boekema PJ, Derijks LJJ, de Boer SY, van de Meeberg PC, Ahmad I, Buiter HJC, and de Boer NK
- Subjects
- Humans, Male, Female, Retrospective Studies, Adult, Middle Aged, Treatment Outcome, Inflammatory Bowel Diseases drug therapy, Follow-Up Studies, Young Adult, Crohn Disease drug therapy, Adolescent, Aged, Mercaptopurine therapeutic use, Azathioprine therapeutic use, Azathioprine adverse effects, Thioguanine therapeutic use
- Abstract
Background: Currently thioguanine is solely used as treatment for inflammatory bowel disease after azathioprine and/or mercaptopurine failure. This study aimed to determine the safety, effectiveness, and 12-month drug survival of thioguanine in thiopurine-naïve patients with inflammatory bowel disease., Methods: A retrospective cohort study was performed in thiopurine-naïve patients with inflammatory bowel disease treated with thioguanine as first thiopurine derivate. Clinical effectiveness was defined as the continuation of thioguanine without the (re)initiation of concurrent biological therapy, systemic corticosteroids, or a surgical intervention. All adverse events were categorized by the Common Terminology Criteria for Adverse Events., Results: A total of 114 patients (male 39%, Crohn's disease 53%) were included with a median treatment duration of 25 months and a median thioguanine dosage of 20 mg/d. Clinical effectiveness at 12 months was observed in 53% of patients, and 78% of these responding patients remained responsive until the end of follow-up. During the entire follow-up period, 26 patients were primary nonresponders, 8 had a secondary loss of response, and 11 patients were unable to cease therapy with systemic corticosteroids within 6 months and were therefore classified as nonresponders. After 12 months, thioguanine was still used by 86% of patients. Fifty (44%) patients developed adverse events (grade 1 or 2) and 9 (8%) patients ceased therapy due to the occurrence of adverse events. An infection was documented in 3 patients, none of them requiring hospitalization and pancytopenia occurred in 2 other patients. No signs of nodular regenerative hyperplasia or portal hypertension were observed., Conclusions: At 12 months, first-line thioguanine therapy was clinically effective in 53% of thiopurine-naïve inflammatory bowel disease patients with an acceptable safety profile., (© 2023 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.)
- Published
- 2024
- Full Text
- View/download PDF
13. Multicentre study and systematic review: Allopurinol exposure during pregnancy.
- Author
-
Crouwel F, Simsek M, de Boer MA, van Asseldonk DP, Bhalla A, Weusthuis ALM, Gilissen LPL, Verburg RJ, Mares WGN, Jharap B, Kuijvenhoven JP, Oldenburg B, Buiter HJC, Julsgaard M, and de Boer NK
- Subjects
- Humans, Pregnancy, Female, Infant, Newborn, Adult, Allopurinol adverse effects, Pregnancy Complications drug therapy, Inflammatory Bowel Diseases drug therapy, Pregnancy Outcome, Abnormalities, Drug-Induced etiology
- Abstract
Background: Data about the safety of allopurinol in pregnant women are sparsely reported., Aims: To investigate the risk of adverse pregnancy outcome and congenital abnormalities after in utero exposure to allopurinol in inflammatory bowel disease (IBD) pregnancies and in general., Methods: We collected safety data of patients with IBD who were treated with allopurinol during pregnancy between January 2013 and March 2022. Additionally, we performed a systematic review about the teratogenic potential of allopurinol., Results: We collected data from 42 allopurinol-exposed pregnancies, including one twin pregnancy; in all women, allopurinol was combined with a thiopurine. Six pregnancies (14.3%) resulted in miscarriage and one in stillbirth at 32 weeks. A congenital anomaly was observed in one newborn (coarctation of the aorta discovered postpartum). Three pregnancies, including the twin pregnancy, ended in moderate preterm delivery and one in very preterm delivery. Five neonates (15.2%) were small for gestational age. From our literature search, we identified an additional 102 allopurinol-exposed pregnancies resulting in 129 live births, including 36 infants from our cohort. Ten infants (7.8%) were born with a congenital anomaly. Two (1.6%) had a comparable pattern of multiple anomalies. The systematic review sub-analysis including only infants born to mothers with IBD (n = 76) revealed that 2.6% of infants had congenital anomalies after in utero exposure to a low dose of allopurinol., Conclusions: Overall, the teratogenicity of allopurinol remains inconclusive. Children conceived by mothers treated for IBD with allopurinol/thiopurine co-therapy do not seem to have an increased risk of congenital anomalies., (© 2024 The Author(s). Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
14. A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
- Author
-
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, and Hoentjen F
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Drug Administration Schedule, Remission Induction, Treatment Outcome, Adalimumab administration & dosage, Adalimumab therapeutic use, Adalimumab adverse effects, Crohn Disease drug therapy, Crohn Disease diagnosis
- Abstract
Background: In the pragmatic open-label randomised controlled non-inferiority LADI trial we showed that increasing adalimumab (ADA) dose intervals was non-inferior to conventional dosing for persistent flares in patients with Crohn's disease (CD) in clinical and biochemical remission., Aims: To develop a prediction model to identify patients who can successfully increase their ADA dose interval based on secondary analysis of trial data., Methods: Patients in the intervention group of the LADI trial increased ADA intervals to 3 and then to 4 weeks. The dose interval increase was defined as successful when patients had no persistent flare (> 8 weeks), no intervention-related severe adverse events, no rescue medication use during the study, and were on an increased dose interval while in clinical and biochemical remission at week 48. Prediction models were based on logistic regression with relaxed LASSO. Models were internally validated using bootstrap optimism correction., Results: We included 109 patients, of which 60.6% successfully increased their dose interval. Patients that were active smokers (odds ratio [OR] 0.90), had previous CD-related intra-abdominal surgeries (OR 0.85), proximal small bowel disease (OR 0.92), an increased Harvey-Bradshaw Index (OR 0.99) or increased faecal calprotectin (OR 0.997) were less likely to successfully increase their dose interval. The model had fair discriminative ability (AUC = 0.63) and net benefit analysis showed that the model could be used to select patients who could increase their dose interval., Conclusion: The final prediction model seems promising to select patients who could successfully increase their ADA dose interval. The model should be validated externally before it may be applied in clinical practice., Clinical Trial Registration Number: ClinicalTrials.gov, number NCT03172377., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
15. [Extra-intestinal manifestations associated with Crohn's disease].
- Author
-
Ayada I, van Wijk MP, de Boer NK, de Hoog J, Kneepkens CMF, and de Meij TJG
- Subjects
- Humans, Eye Diseases etiology, Eye Diseases diagnosis, Quality of Life, Skin Diseases etiology, Skin Diseases diagnosis, Crohn Disease complications, Crohn Disease diagnosis
- Abstract
Extra-intestinal manifestations (EIM) associated with Crohn's disease (CD) are frequently observed and can manifest as either the initial symptom or develop later in the disease course following gastrointestinal symptoms. The most common EIM affect the joints, skin, or eyes, with some correlating with active CD activity while others may occur during periods of inactivity. EIM can affect both pediatric and adult CD patients, potentially reducing their quality of life if not promptly identified and treated. Thus, emphasizing the prevalence and clinical presentation is essential to initiate appropriate diagnostic assessments and effectively treat both EIM and the underlying CD. In this case series, we present two pediatric and one adult case where EIM preceded CD diagnosis, resulting in delayed CD diagnosis. Additionally, we outline the most prevalent EIM, their epidemiology, and associated symptoms.
- Published
- 2024
16. The Potential of Fecal Volatile Organic Compound Analysis for the Early Diagnosis of Late-Onset Sepsis in Preterm Infants: A Narrative Review.
- Author
-
de Kroon RR, Frerichs NM, Struys EA, de Boer NK, de Meij TGJ, and Niemarkt HJ
- Subjects
- Humans, Infant, Newborn, Gastrointestinal Microbiome physiology, Volatile Organic Compounds analysis, Feces microbiology, Feces chemistry, Infant, Premature, Early Diagnosis, Sepsis diagnosis, Sepsis microbiology
- Abstract
Early diagnosis and treatment of late-onset sepsis (LOS) is crucial for survival, but challenging. Intestinal microbiota and metabolome alterations precede the clinical onset of LOS, and the preterm gut is considered an important source of bacterial pathogens. Fecal volatile organic compounds (VOCs), formed by physiologic and pathophysiologic metabolic processes in the preterm gut, reflect a complex interplay between the human host, the environment, and microbiota. Disease-associated fecal VOCs can be detected with an array of devices with various potential for the development of a point-of-care test (POCT) for preclinical LOS detection. While characteristic VOCs for common LOS pathogens have been described, their VOC profiles often overlap with other pathogens due to similarities in metabolic pathways, hampering the construction of species-specific profiles. Clinical studies have, however, successfully discriminated LOS patients from healthy individuals using fecal VOC analysis with the highest predictive value for Gram-negative pathogens. This review discusses the current advancements in the development of a non-invasive fecal VOC-based POCT for early diagnosis of LOS, which may potentially provide opportunities for early intervention and targeted treatment and could improve clinical neonatal outcomes. Identification of confounding variables impacting VOC synthesis, selection of an optimal detection device, and development of standardized sampling protocols will allow for the development of a novel POCT in the near future.
- Published
- 2024
- Full Text
- View/download PDF
17. Exploring the role of oxidative stress and the effect of N-acetylcysteine in thiopurine-induced liver injury in inflammatory bowel disease: A randomized crossover pilot study.
- Author
-
van Asseldonk DP, Crouwel F, Seinen ML, Scheffer PG, Veldkamp AI, de Boer NK, Lissenberg-Witte B, Peters GJ, and van Bodegraven AA
- Subjects
- Humans, Acetylcysteine therapeutic use, Immunosuppressive Agents, Peroxidase, Pilot Projects, Cross-Over Studies, Chemical and Drug Induced Liver Injury, Chronic, Inflammatory Bowel Diseases drug therapy, Purines adverse effects, Sulfhydryl Compounds adverse effects
- Abstract
Thiopurine treatment is regularly complicated by drug-induced liver injury. It has been suggested that oxidative stress may play a synergistic role. To assess whether thiopurine-induced liver injury coincides with increased oxidative stress and whether co-administration with N-acetylcysteine is protective, we performed a randomized open label crossover pilot study in inflammatory bowel disease patients with thiopurine-induced increased serum liver tests. The study comprised four stages of 4 weeks. Patients received no additional therapy followed by N-acetylcysteine 1200 mg twice a day, or the other way around, alongside ongoing thiopurine treatment. The third and fourth stages comprised a washout period and thiopurine reintroduction period. Nine patients completed the study, and the addition of N-acetylcysteine decreased myeloperoxidase concentrations (33.6-24.5 pmol/L, p = 0.038). The other biomarkers remained unchanged, including thiopurine metabolites, xanthine oxidase activity, thiopurine S-methyltransferase activity and serum liver enzyme activity tests. Reintroduction of thiopurines led to an increase of F2-isoprostanes (101-157 ng/mmol, p = 0.038), but not of serum liver enzyme activity tests. Results suggests that thiopurines may increase oxidative stress and although the addition of N-acetylcysteine led to a decrease in plasma myeloperoxidase concentrations, it does not protect from thiopurine-induced increase of serum liver tests., (© 2024 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).)
- Published
- 2024
- Full Text
- View/download PDF
18. Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.
- Author
-
Jansen FM, van Linschoten RCA, Kievit W, Smits LJT, Pauwels RWM, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, Hoentjen F, and van der Woude CJ
- Subjects
- Adult, Humans, Adalimumab therapeutic use, Cost-Effectiveness Analysis, Quality of Life, Antibodies, Monoclonal, Humanized therapeutic use, Treatment Outcome, Cost-Benefit Analysis, Crohn Disease drug therapy
- Abstract
Background and Aims: We aimed to assess cost-effectiveness of increasing adalimumab dose intervals compared to the conventional dosing interval in patients with Crohn's disease [CD] in stable clinical and biochemical remission., Design: We conducted a pragmatic, open-label, randomized controlled non-inferiority trial, comparing increased adalimumab intervals with the 2-weekly interval in adult CD patients in clinical remission. Quality of life was measured with the EQ-5D-5L. Costs were measured from a societal perspective. Results are shown as differences and incremental net monetary benefit [iNMB] at relevant willingness to accept [WTA] levels., Results: We randomized 174 patients to the intervention [n = 113] and control [n = 61] groups. No difference was found in utility (difference: -0.017, 95% confidence interval [-0.044; 0.004]) and total costs (-€943, [-€2226; €1367]) over the 48-week study period between the two groups. Medication costs per patient were lower (-€2545, [-€2780; -€2192]) in the intervention group, but non-medication healthcare (+€474, [+€149; +€952]) and patient costs (+€365 [+€92; €1058]) were higher. Cost-utility analysis showed that the iNMB was €594 [-€2099; €2050], €69 [-€2908; €1965] and -€455 [-€4,096; €1984] at WTA levels of €20 000, €50 000 and €80 000, respectively. Increasing adalimumab dose intervals was more likely to be cost-effective at WTA levels below €53 960 per quality-adjusted life year. Above €53 960 continuing the conventional dose interval was more likely to be cost-effective., Conclusion: When the loss of a quality-adjusted life year is valued at less than €53 960, increasing the adalimumab dose interval is a cost-effective strategy in CD patients in stable clinical and biochemical remission., Clinical Trial Registration Number: ClinicalTrials.gov, number NCT03172377., (© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.)
- Published
- 2023
- Full Text
- View/download PDF
19. Impact of timing of primary ileocecal resection on prognosis in patients with Crohn's disease.
- Author
-
Beelen EMJ, Arkenbosch JHC, Erler NS, Sleutjes JAM, Hoentjen F, Bodelier AGL, Dijkstra G, Romberg-Camps M, de Boer NK, Stassen LPS, van der Meulen AE, West R, van Ruler O, van der Woude CJ, and de Vries AC
- Subjects
- Humans, Ileum surgery, Cecum surgery, Cecum pathology, Prognosis, Crohn Disease surgery, Inflammatory Bowel Diseases
- Abstract
Background: The advantage of early ileocecal resection after Crohn's disease diagnosis is a matter of debate. This study aims to assess the timing of ileocecal resection on prognosis, after correction for possible confounders., Methods: Patients with Crohn's disease with primary ileocecal resection between 2000 and 2019 were included in a retrospective multicentre cohort. The primary endpoint was endoscopic recurrence (Rutgeerts score ≥i2b) within 18 months. Secondary endpoints were escalation of inflammatory bowel disease medication within 18 months and re-resection during follow-up. The association between timing of ileocecal resection and these endpoints was investigated using multivariable proportional hazard models, corrected for covariates including Montreal classification, postoperative prophylaxis, smoking, indication for surgery, medication before ileocecal resection, perianal fistulas, surgical approach, histology, length of resected segment and calendar year., Results: In 822 patients ileocecal resection was performed after a median of 3.1 years (i.q.r. 0.7-8.0) after Crohn's disease diagnosis. The lowest incidence of endoscopic recurrence, escalation of inflammatory bowel disease medication and re-resection was observed for patients undergoing ileocecal resection shortly after diagnosis (0-1 months). After correction for covariates, patients with ileocecal resection at 0, 4 and 12 months after diagnosis had a cumulative incidence of 35 per cent, 48 per cent and 39 per cent for endoscopic recurrence, 20 per cent, 29 per cent and 28 per cent for escalation of inflammatory bowel disease medication and 20 per cent, 30 per cent and 34 per cent for re-resection, respectively. In the multivariable model ileocolonic disease (HR 1.39 (95 per cent c.i. 1.05 to 1.86)), microscopic inflammation of proximal and distal resection margins (HR 2.20 (95 per cent c.i. 1.21 to 3.87)) and postoperative prophylactic biological and immunomodulator (HR 0.16 (95 per cent c.i. 0.05 to 0.43)) were associated with endoscopic recurrence., Conclusion: The timing of ileocecal resection was not associated with a change of disease course; in the multivariable model, the postoperative recurrence was not affected by timing of ileocecal resection., (© The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
20. Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease.
- Author
-
Kreijne JE, Goetgebuer RL, Erler NS, De Boer NK, Siebers AG, Dijkstra G, van Kemenade FA, Hoentjen F, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Pierik MJ, van der Woude CJ, and de Vries AC
- Subjects
- Adult, Humans, Female, Early Detection of Cancer, Immunosuppressive Agents adverse effects, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms pathology, Uterine Cervical Dysplasia complications, Uterine Cervical Dysplasia diagnosis, Uterine Cervical Dysplasia pathology, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases drug therapy, Papillomavirus Infections complications, Papillomavirus Infections diagnosis
- Abstract
Background: Women with inflammatory bowel disease (IBD) are at increased risk of high-grade cervical intraepithelial neoplasia and cervical cancer (CIN2+)., Aim: To assess the association between cumulative exposure to immunomodulators (IM) and biologic agents (BIO) for IBD and CIN2+ METHODS: Adult women diagnosed with IBD before December 31st 2016 in the Dutch IBD biobank with available cervical records in the nationwide cytopathology database were identified. CIN2+ incidence rates in IM- (i.e., thiopurines, methotrexate, tacrolimus and cyclosporine) and BIO- (anti-tumour necrosis factor, vedolizumab and ustekinumab) exposed patients were compared to unexposed patients and risk factors were assessed. Cumulative exposure to immunosuppressive drugs was evaluated in extended time-dependent Cox-regression models., Results: The study cohort comprised 1981 women with IBD: 99 (5%) developed CIN2+ during median follow-up of 17.2 years [IQR 14.6]. In total, 1305 (66%) women were exposed to immunosuppressive drugs (IM 58%, BIO 40%, IM and BIO 33%). CIN2+ risk increased per year of exposure to IM (HR 1.16, 95% CI 1.08-1.25). No association was observed between cumulative exposure to BIO or both BIO and IM and CIN2+. In multivariate analysis, smoking (HR 2.73, 95%CI 1.77-4.37) and 5-yearly screening frequency (HR 1.74, 95% CI 1.33-2.27) were also risk factors for CIN2+ detection., Conclusion: Cumulative exposure to IM is associated with increased risk of CIN2+ in women with IBD. In addition to active counselling of women with IBD to participate in cervical screening programs, further assessment of the benefit of intensified screening of women with IBD on long-term IM exposure is warranted., (© 2023 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
21. Endoscopic and surgical treatment outcomes of colitis-associated advanced colorectal neoplasia: a multicenter cohort study.
- Author
-
Derks ME, Te Groen M, Peters CP, Dijkstra G, de Vries AC, Romkens TE, Horjus CS, de Boer NK, Bemelman WA, Nagtegaal ID, Derikx LA, and Hoentjen F
- Subjects
- Humans, Cohort Studies, Colonoscopy, Colectomy adverse effects, Treatment Outcome, Retrospective Studies, Colorectal Neoplasms pathology, Colitis etiology, Colitis pathology, Colitis surgery, Colitis, Ulcerative surgery, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases pathology, Inflammatory Bowel Diseases surgery, Colonic Neoplasms surgery
- Abstract
Background: Inflammatory bowel disease (IBD) patients are at increased risk of advanced neoplasia (high-grade dysplasia or colorectal cancer). The authors aimed to (1) assess synchronous and metachronous neoplasia following (sub)total or proctocolectomy, partial colectomy or endoscopic resection for advanced neoplasia in IBD, and (2) identify factors associated with treatment choice., Material and Methods: In this retrospective multicenter cohort study, the authors used the Dutch nationwide pathology databank (PALGA) to identify patients diagnosed with IBD and colonic advanced neoplasia (AN) between 1991 and 2020 in seven hospitals in the Netherlands. Logistic and Fine & Gray's subdistribution hazard models were used to assess adjusted subdistribution hazard ratios for metachronous neoplasia and associations with treatment choice., Results: The authors included 189 patients (high-grade dysplasia n =81; colorectal cancer n =108). Patients were treated with proctocolectomy ( n =33), (sub)total colectomy ( n =45), partial colectomy ( n =56) and endoscopic resection ( n =38). Partial colectomy was more frequently performed in patients with limited disease and older age, with similar patient characteristics between Crohn's disease and ulcerative colitis. Synchronous neoplasia was found in 43 patients (25.0%; (sub)total or proctocolectomy n =22, partial colectomy n =8, endoscopic resection n =13). The authors found a metachronous neoplasia rate of 6.1, 11.5 and 13.7 per 100 patient-years after (sub)total colectomy, partial colectomy and endoscopic resection, respectively. Endoscopic resection, but not partial colectomy, was associated with an increased metachronous neoplasia risk (adjusted subdistribution hazard ratios 4.16, 95% CI 1.64-10.54, P <0.01) compared with (sub)total colectomy., Conclusion: After confounder adjustment, partial colectomy yielded a similar metachronous neoplasia risk compared to (sub)total colectomy. High metachronous neoplasia rates after endoscopic resection underline the importance of strict subsequent endoscopic surveillance., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
22. Rectally Administrated Thioguanine for Distal Ulcerative Colitis: A Multicenter Case Series.
- Author
-
Crouwel F, Simsek M, van Doorn AS, Mulder CJJ, Buiter HJC, Barclay ML, Florin TH, and de Boer NK
- Subjects
- Humans, Thioguanine adverse effects, Colitis, Ulcerative drug therapy, Colitis
- Published
- 2023
- Full Text
- View/download PDF
23. Duration of Neonatal Antibiotic Exposure in Preterm Infants in Association with Health and Developmental Outcomes in Early Childhood.
- Author
-
Deianova N, de Boer NK, Aoulad Ahajan H, Verbeek C, Aarnoudse-Moens CSH, Leemhuis AG, van Weissenbruch MM, van Kaam AH, Vijbrief DC, Hulzebos CV, Giezen A, Cossey V, de Boode WP, de Jonge WJ, Benninga MA, Niemarkt HJ, and de Meij TGJ
- Abstract
Over 90% of preterm neonates are, often empirically, exposed to antibiotics as a potentially life-saving measure against sepsis. Long-term outcome in association with antibiotic exposure (NABE) has insufficiently been studied after preterm birth. We investigated the association of NABE-duration with early-childhood developmental and health outcomes in preterm-born children and additionally assessed the impact of GA on outcomes. Preterm children (GA < 30 weeks) participating in a multicenter cohort study were approached for follow-up. General expert-reviewed health questionnaires on respiratory, atopic and gastrointestinal symptoms were sent to parents of children > 24 months' corrected age (CA). Growth and developmental assessments (Bayley Scales of Infant and Toddler Development (BSID) III) were part of standard care assessment at 24 months' CA. Uni- and multivariate regressions were performed with NABE (per 5 days) and GA (per week) as independent variables. Odds ratios (OR) for health outcomes were adjusted (aOR) for confounders, where appropriate. Of 1079 infants whose parents were approached, 347 (32%) responded at a mean age of 4.6 years (SD 0.9). In children with NABE (97%), NABE duration decreased by 1.6 days ( p < 0.001) per week of gestation. Below-average gross-motor development (BSID-III gross-motor score < 8) was associated with duration of NABE (aOR = 1.28; p = 0.04). The aOR for constipation was 0.81 ( p = 0.04) per gestational week. Growth was inversely correlated with GA. Respiratory and atopic symptoms were not associated with NABE, nor GA. We observed that prolonged NABE after preterm birth was associated with below-average gross-motor development at 24 months' CA, while a low GA was associated with lower weight and stature Z-scores and higher odds for constipation.
- Published
- 2023
- Full Text
- View/download PDF
24. Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease.
- Author
-
Crouwel F, Simsek M, de Boer MA, Mulder CJJ, van Andel EM, Creemers RH, van Asseldonk DP, van Bodegraven AA, Horjus CS, Visschedijk MC, Weusthuis ALM, Seinen ML, Jharap B, van Schaik FDM, Ahmad I, Boekema PJ, Tack GJ, Wormmeester L, Lutgens MWMD, van Boeckel PGA, Gilissen LPL, Kerkhof M, Russel MGVM, Hoentjen F, Bartelink ME, Kuijvenhoven JP, Maljaars JWJ, van Dop WA, Wonders J, van der Voorn MMPJA, Buiter HJC, and de Boer NK
- Subjects
- Pregnancy, Infant, Newborn, Child, Humans, Female, Adult, Thioguanine adverse effects, Pregnancy Outcome epidemiology, Stillbirth epidemiology, Inflammatory Bowel Diseases drug therapy, Abortion, Spontaneous chemically induced, Abortion, Spontaneous epidemiology, Pregnancy Complications drug therapy, Pregnancy Complications epidemiology
- Abstract
Background: Safety of thioguanine in pregnant patients with inflammatory bowel disease [IBD] is sparsely recorded. This study was aimed to document the safety of thioguanine during pregnancy and birth., Methods: In this multicentre case series, IBD patients treated with thioguanine during pregnancy were included. Data regarding disease and medication history, pregnancy course, obstetric complications, and neonatal outcomes were collected., Results: Data on 117 thioguanine-exposed pregnancies in 99 women were collected. Most [78%] had Crohn's disease and the mean age at delivery was 31 years. In 18 pregnancies [15%], IBD flared. Obstetric and infectious complications were seen in 15% [n = 17] and 7% [n = 8] of pregnancies, respectively. Ten pregnancies [8.5%] resulted in a first trimester miscarriage, one in a stillbirth at 22 weeks of gestational age and one in an induced abortion due to trisomy 21. In total, 109 neonates were born from 101 singleton pregnancies and four twin pregnancies. One child was born with a congenital abnormality [cleft palate]. In the singleton pregnancies, 10 children were born prematurely and 10 were born small for gestational age. Screening for myelosuppresion was performed in 16 neonates [14.7%]; two had anaemia in umbilical cord blood. All outcomes were comparable to either the general Dutch population or to data from three Dutch cohort studies on the use of conventional thiopurines in pregnant IBD patients., Conclusion: In this large case series, the use of thioguanine during pregnancy is not associated in excess with adverse maternal or neonatal outcomes., (© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.)
- Published
- 2023
- Full Text
- View/download PDF
25. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
- Author
-
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, and Hoentjen F
- Subjects
- Adult, Humans, Male, Female, Adolescent, Adalimumab therapeutic use, C-Reactive Protein, Methotrexate therapeutic use, Netherlands, Crohn Disease drug therapy
- Abstract
Background: Despite its effectiveness in treating Crohn's disease, adalimumab is associated with an increased risk of infections and high health-care costs. We aimed to assess clinical outcomes of increased adalimumab dose intervals versus conventional dosing in patients with Crohn's disease in stable remission., Methods: The LADI study was a pragmatic, open-label, multicentre, non-inferiority, parallel, randomised controlled trial, done in six academic hospitals and 14 general hospitals in the Netherlands. Adults (aged ≥18 years) diagnosed with luminal Crohn's disease (with or without concomitant perianal disease) were eligible when in steroid-free clinical and biochemical remission (defined as Harvey-Bradshaw Index [HBI] score <5, faecal calprotectin <150 μg/g, and C-reactive protein <10 mg/L) for at least 9 months on a stable dose of 40 mg subcutaneous adalimumab every 2 weeks. Patients were randomly assigned (2:1) to the intervention group or control group by the coordinating investigator using a secure web-based system with variable block randomisation (block sizes of 6, 9, and 12). Randomisation was stratified on concomitant use of thiopurines and methotrexate. Patients and health-care providers were not masked to group assignment. Patients allocated to the intervention group increased adalimumab dose intervals to 40 mg every 3 weeks at baseline and further to every 4 weeks if they remained in clinical and biochemical remission at week 24. Patients in the control group continued their 2-weekly dose interval. The primary outcome was the cumulative incidence of persistent flares at week 48 defined as the presence of at least two of the following criteria: HBI score of 5 or more, C-reactive protein 10 mg/L or more, and faecal calprotectin more than 250 μg/g for more than 8 weeks and a concurrent decrease in the adalimumab dose interval or start of escape medication. The non-inferiority margin was 15% on a risk difference scale. All analyses were done in the intention-to-treat and per-protocol populations. This trial was registered at ClinicalTrials.gov, NCT03172377, and is not recruiting., Findings: Between May 3, 2017, and July 6, 2020, 174 patients were randomly assigned to the intervention group (n=113) or the control group (n=61). Four patients from the intervention group and one patient from the control group were excluded from the analysis for not meeting inclusion criteria. 85 (50%) of 169 participants were female and 84 (50%) were male. At week 48, the cumulative incidence of persistent flares in the intervention group (three [3%] of 109) was non-inferior compared with the control group (zero; pooled adjusted risk difference 1·86% [90% CI -0·35 to 4·07). Seven serious adverse events occurred, all in the intervention group, of which two (both patients with intestinal obstruction) were possibly related to the intervention. Per 100 person-years, 168·35 total adverse events, 59·99 infection-related adverse events, and 42·57 gastrointestinal adverse events occurred in the intervention group versus 134·67, 75·03, and 5·77 in the control group, respectively., Interpretation: The individual benefit of increasing adalimumab dose intervals versus the risk of disease recurrence is a trade-off that should take patient preferences regarding medication and the risk of a flare into account., Funding: Netherlands Organisation for Health Research and Development., Competing Interests: Declaration of interests FMJ has received a research grant from ZonMW. DJdJ has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Galapagos and held leadership roles in the Dutch Initiative on Crohn and Colitis and the IBD workgroup of the Dutch Gastroenterology Society. ACdV has received research grants from Takeda, Janssen, and Pfizer. RLW has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Ferring, Pfizer, Galapagos, AbbVie, and Janssen. TEHR has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie and has participated in the advisory board for Galapagos. MWMDL has received a grant for podcasts from Pfizer; received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen-Cilag and Galapagos; participated in advisory boards of BMS and Galapagos; and held leadership roles in the Elisabeth Twee Steden Ziekenhuis. AAvB has received research grants from AbbVie, Celgene/BMS, Janssen, Pfizer, Teva, and ZonMW; consulting fees from Ferring, Galapagos, AbbVie, and BMS; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Ferring, Galapagos, and Janssen; support for attending meetings from Janssen; and held leadership roles in committees of the Dutch Gastroenterology Society and National Federation of Medical Specialists. BO has received research grants from Galapagos, Takeda, Ferring, and Celltrion; received consulting fees from AbbVie, Galapagos, Pfizer, Ferring, Takeda, and Janssen; received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Takeda, Galapagos, AbbVie, and Ferring; and was chairman of the IBD Committee of the Dutch Association of Gastroenterology. MJP has received consulting fees from Takeda, Janssen, Galapagos, and AbbVie; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen. NKdB has received research grants from Teva, Takeda, and the Dutch Gastroenterology and Hepatology Patient Association (MLDS); and has received consulting fees from Teva. RCM-H has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen-Cilag and is a member of the national IBD Committee of the Dutch Association for Gastroenterology and Hepatology. AEvdM-dJ has received research grants from Galapagos, Nestle, Cablon, and Norgine; has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Galapagos, Tramedico, and Janssen-Cilag; and has participated in an advisory board for Ferring. FH has received research grants from Janssen, AbbVie, Pfizer, and Takeda; and has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Janssen, Takeda, and Pfizer. CJvdW has received research grants from ZonMW, Falk, and Pfizer; has received consulting fees from Janssen, Galapagos, and Pfizer; has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Ferring and AbbVie; and had leadership roles in the European Crohn's and Colitis Organisation, United European Gastroenterology Council, and the Dutch Association for Gastroenterology. All other authors declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
26. The Reliability of Patient-Performed Fecal Calprotectin Testing in Inflammatory Bowel Disease.
- Author
-
Dijkhuis LEJL, Crouwel F, Duijvestein M, Buiter HJC, de Boer NK, and Hamer HM
- Subjects
- Humans, Cross-Sectional Studies, Prospective Studies, Reproducibility of Results, Feces, Leukocyte L1 Antigen Complex, Inflammatory Bowel Diseases diagnosis
- Abstract
Background: Home use of a buffer-containing extraction device for fecal calprotectin determination can bypass the labor-intensive extraction procedure and potentially prevent degradation at room temperature., Methods: In this prospective cross-sectional observational study, 2 CALiaGold tubes (extraction device) and one native tube were filled from the same bowel movement by patients with inflammatory bowel disease. Afterwards patients completed a questionnaire including whether they preferred the extraction device or the normal sampling method. All tubes were sent to the laboratory and when they arrived, 2 more CALiaGold tubes were filled at the laboratory from the native sample. The fecal calprotectin concentrations in all tubes were measured by a particle-enhanced turbidimetric immunoassay., Results: Fifty-three patients were included in the study. Fecal calprotectin levels were significantly higher in samples extracted by the patient compared to the analyst-performed extractions. When patients were divided into 3 groups (i.e., fecal calprotectin levels <50 ug/g, 50 to 200 µg/g, and >200 µg/g) a substantial concordance was found (Cohen kappa 0.654). Patients sampling imprecision was higher (P < 0.018, median CV 16%) compared to the analyst. Most patients preferred this extraction device., Conclusions: Patient-performed fecal calprotectin extraction seems a realistic alternative sampling method and is preferred by most patients., (© American Association for Clinical Chemistry 2022.)
- Published
- 2023
- Full Text
- View/download PDF
27. Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn's disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy.
- Author
-
Ten Bokkel Huinink S, Beelen EMJ, Ten Bokkel Huinink T, Hoentjen F, G L Bodelier A, Dijkstra G, Romberg-Camps M, de Boer NK, Stassen LPS, van der Meulen AE, West R, van Ruler O, van der Woude CJ, and de Vries AC
- Subjects
- Humans, Cohort Studies, Tumor Necrosis Factor Inhibitors adverse effects, Immunologic Factors therapeutic use, Tumor Necrosis Factor-alpha, Retreatment, Necrosis, Crohn Disease diagnosis, Crohn Disease drug therapy, Crohn Disease surgery
- Abstract
Background: A considerable proportion of Crohn's disease patients that undergo ileocecal resection (ICR) have failed anti-tumor necrosis factor (TNF) therapy preoperatively. This study aimed to assess the effectiveness of retreatment of anti-TNF therapy in patients with postoperative recurrence., Methods: A real-world cohort study was performed on Crohn's disease patients who underwent primary ICR after anti-TNF therapy failure, and who were retreated with anti-TNF therapy for postoperative symptomatic Crohn's disease. The primary outcome was treatment failure (the need for (re)introduction of corticosteroids, immunosuppressants, or biologicals or the need for re-resection). Sub-analyses were performed on the nature of preoperative anti-TNF failure (primary non-response, secondary loss of response, intolerance), indication for ICR (refractory, stricturing, penetrating disease), combination therapy with immunomodulators, retreatment with the same anti-TNF agent and preoperative exposure to 1 vs. >1 anti-TNF agents., Results: In total, 66 of 364 patients retreated with anti-TNF therapy following ICR. Cumulative rates of treatment failure at 1 and 2 years were 28% and 47%. Treatment failure rate at 2 years was significantly lower in patients receiving combination therapy as compared to anti-TNF monotherapy (30% vs. 49%, P = 0.02). No difference in treatment failure was found with regards to the nature of preoperative anti-TNF failure (P = 0.76), indication for ICR (P = 0.88) switch of anti-TNF agent (P = 0.55) agent, and preoperative exposure to 1 vs. >1 anti-TNF agents (P = 0.88)., Conclusion: Retreatment with anti-TNF therapy for postoperative Crohn's disease recurrence is a valid strategy after preoperative failure. Combination therapy is associated with a lower rate of treatment failure., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
28. Impact of Preanalytical Factors on Calprotectin Concentration in Stool: A Multiassay Comparison.
- Author
-
Hamer HM, Mulder AHL, de Boer NK, Crouwel F, van Rheenen PF, Spekle M, Vermeer M, Wagenmakers-Huizinga L, and Muller Kobold AC
- Subjects
- Humans, Reproducibility of Results, Feces chemistry, Enzyme-Linked Immunosorbent Assay methods, Leukocyte L1 Antigen Complex analysis, Inflammatory Bowel Diseases
- Abstract
Background: Measuring calprotectin concentration in stool is increasingly important in monitoring disease activity and treatment response in inflammatory bowel disease. This study evaluates the impact of preanalytical storage conditions on reliability of calprotectin testing using 5 different calprotectin immunoassays., Methods: Aliquots of homogenized fresh fecal samples in untreated or extracted form were stored at room temperature or 4°C. Calprotectin concentration was measured day 0 to 4 and 8. Five different immunoassays and accompanying extraction buffers were used (CALiaGold, Phadia EliA, Bühlmann fCal turbo, ELISA Bühlmann, Inova Quanta Flash). Repeated measurements of change from baseline calprotectin levels over time were analyzed using a mixed model analysis., Results: Calprotectin concentrations declined over time under all preanalytical conditions with all assays, except for extracted feces stored at 4°C. The rate of decline was greatest in untreated stool kept at room temperature, reaching significant difference from baseline already after 1 day (P < 0.001). In extracted feces kept at room temperature, significant difference from baseline was reached after 2 days, and in untreated feces at 4°C, after 4 days. However, the results differed significantly between assays. After 4 days of storage at room temperature, the mean calprotectin decline from baseline differed between 30% and 60%, dependent on the assay used., Conclusions: Fecal calprotectin concentration in stool samples declines over time, and the rate of decline is greater at higher temperatures. In extracted feces stored at 4°C, calprotectin is most stable. It is assay-dependent how long extracted feces stored at 4°C give reliable test results., Competing Interests: Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest: Employment or Leadership: None declared. Consultant or Advisory Role: None declared. Stock Ownership: None declared. Honoraria: None declared. Research Funding: Sysmex Europe GmbH facilitated the design of the study. Sysmex Nederland B.V. and Abbott Laboratories funded the kits used in the present study. These organizations played no role in analysis and interpretation of data, writing of the report, or in the decision to submit the findings for publication. P.F.v.R. received funding from Bühlmann laboratories for other projects. Other authors have no financial disclosures or conflicts of interest. Expert Testimony: None declared. Patents: None declared., (© American Association for Clinical Chemistry 2022.)
- Published
- 2022
- Full Text
- View/download PDF
29. Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease.
- Author
-
Ten Bokkel Huinink S, de Jong DC, Nieboer D, Thomassen D, Steyerberg EW, Dijkgraaf MGW, Bodelier AGL, West RL, Römkens TEH, Hoentjen F, Mallant RC, van Tuyl BAC, Mares WGN, Wolfhagen FHJ, Dijkstra G, Reijnders JGP, de Boer NK, Tan ACITL, van Boeckel PGA, Tack GJ, van Asseldonk DP, D'Haens GRAM, van der Woude CJ, Duijvestein M, and de Vries AC
- Subjects
- Humans, Models, Statistical, Recurrence, Reproducibility of Results, Retrospective Studies, Risk Assessment, Crohn Disease drug therapy, Tumor Necrosis Factor Inhibitors therapeutic use, Withholding Treatment
- Abstract
Background: Anti-tumor necrosis factor (TNF) therapy is effective for the treatment of Crohn's disease. Cessation may be considered in patients with a low risk of relapse. We aimed to externally validate and update our previously developed prediction model to estimate the risk of relapse after cessation of anti-TNF therapy., Methods: We performed a retrospective cohort study in 17 Dutch hospitals. Crohn's disease patients in clinical, biochemical or endoscopic remission were included after anti-TNF cessation. Primary outcome was a relapse necessitating treatment. Discrimination and calibration of the previously developed model were assessed. After external validation, the model was updated. The performance of the updated prediction model was assessed in internal-external validation and by using decision curve analysis., Results: 486 patients were included with a median follow-up of 1.7 years. Relapse rates were 35 and 54% after 1 and 2 years. At external validation, the discriminative ability of the prediction model was equal to that found at the development of the model [c-statistic 0.58 (95% confidence interval (CI) 0.54-0.62)], though the model was not well-calibrated on our cohort [calibration slope: 0.52 (0.28-0.76)]. After an update, a c-statistic of 0.60 (0.58-0.63) and calibration slope of 0.89 (0.69-1.09) were reported in internal-external validation., Conclusion: Our previously developed and updated prediction model for the risk of relapse after cessation of anti-TNF in Crohn's disease shows reasonable performance. The use of the model may support clinical decision-making to optimize patient selection in whom anti-TNF can be withdrawn. Clinical validation is ongoing in a prospective randomized trial., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
30. Salivary Calprotectin Is not a Useful Biomarker to Monitor Disease Activity in Patients with Inflammatory Bowel Disease.
- Author
-
Bos V, Crouwel F, Waaijenberg P, Bouma G, Duijvestein M, Buiter HJ, Brand HS, Hamer HM, and De Boer NK
- Subjects
- Biomarkers, Cohort Studies, Cross-Sectional Studies, Feces, Humans, Leukocyte L1 Antigen Complex, Severity of Illness Index, Colitis, Ulcerative diagnosis, Inflammatory Bowel Diseases diagnosis
- Abstract
Background and Aims: Non-invasive biomarkers are gaining interest for monitoring disease activity in patients with inflammatory bowel diseases (IBD). Fecal calprotectin is a reliable biomarker but patients often report the collection of feces being unpleasant and cumbersome. In this study, we aimed to assess if salivary calprotectin could be used as a non-invasive biomarker to determine disease activity instead of fecal calprotectin., Methods: In this cross-sectional explorative cohort study, stimulated saliva was collected from patients with an established IBD diagnosis and healthy controls. The concentration of calprotectin in saliva was determined by a particle-enhanced turbidimetric immunoassay. Intestinal disease activity was assessed with fecal calprotectin levels and the Harvey-Bradshaw Index (HBI) or Simple Clinical Colitis Activity Index (SCCAI). Missing data were handled using multiple imputation., Results: Sixty-three patients (41 Crohn's disease and 22 ulcerative colitis) and 11 controls were included. Patients had a mean fecal calprotectin of 138.78 µg/g and a median salivary calprotectin of 1.87 mg/L. No significant correlation was found between salivary calprotectin and fecal calprotectin levels (p=0.495). When patients were stratified in two subgroups based on a fecal calprotectin cut-off value of 250 µg/g, there were no significant differences in salivary calprotectin levels between both patient groups (p=0.641) and between patients and healthy controls (p=0.248). Also, salivary, and fecal calprotectin levels were not significantly different when stratifying patients in two subgroups, active disease and remission, using HBI/SCCAI scores., Conclusions: Salivary calprotectin does not correlate to fecal calprotectin and disease activity scores in patients, making it unreliable for assessing IBD activity.
- Published
- 2022
- Full Text
- View/download PDF
31. Favourable Tolerability and Drug Survival of Tioguanine Versus Methotrexate After Failure of Conventional Thiopurines in Crohn's Disease.
- Author
-
Savelkoul EHJ, Maas MHJ, Bourgonje AR, Crouwel F, Biemans VBC, den Broeder N, Russel MGVM, Römkens TEH, de Boer NK, Dijkstra G, and Hoentjen F
- Subjects
- Humans, Immunosuppressive Agents adverse effects, Methotrexate adverse effects, Retrospective Studies, Treatment Outcome, Crohn Disease chemically induced, Crohn Disease drug therapy, Thioguanine adverse effects
- Abstract
Background and Aims: Both methotrexate and tioguanine can be considered as treatment options in patients with Crohn's disease after failure of conventional thiopurines. This study aimed to compare tolerability and drug survival of methotrexate and tioguanine therapy after failure of conventional thiopurines in patients with Crohn's disease., Methods: We conducted a retrospective, multicentre study, including patients with Crohn's disease initiating monotherapy methotrexate or tioguanine after failure [all causes] of conventional thiopurines. Follow-up duration was 104 weeks or until treatment discontinuation. The primary outcome was cumulative therapy discontinuation incidence due to adverse events. Secondary outcomes included total number of [serious] adverse events, and ongoing monotherapy., Results: In total, 219 patients starting either methotrexate [n = 105] or tioguanine [n = 114] were included. In all 65 [29.7%] patients (methotrexate 43.8% [46/105 people], tioguanine 16.7% [19/114 people], p <0.001) discontinued their treatment due to adverse events during follow-up. Median time until discontinuation due to adverse events was 16 weeks (interquartile range [IQR] 7-38, p = 0.812). Serious adverse events were not significantly different. Patients treated with methotrexate experienced adverse events more often [methotrexate 83%, tioguanine 46%, p <0.001]. Total monotherapy drug survival after 104 weeks was 22% for methotrexate and 46% for tioguanine [p <0.001]., Conclusions: We observed a higher cumulative discontinuation incidence due to adverse events for methotrexate [44%] compared with tioguanine [17%] in Crohn's disease patients after failure of conventional thiopurines. The total adverse events incidence during methotrexate use was higher, whereas serious adverse events incidence was similar. These favourable results for tioguanine treatment may guide the selection of immunosuppressive therapy after failure of conventional thiopurines., (© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.)
- Published
- 2022
- Full Text
- View/download PDF
32. Esophageal microbiota composition and outcome of esophageal cancer treatment: a systematic review.
- Author
-
Plat VD, van Rossen TM, Daams F, de Boer NK, de Meij TGJ, Budding AE, Vandenbroucke-Grauls CMJE, and van der Peet DL
- Subjects
- Chemotherapy, Adjuvant, Humans, Neoadjuvant Therapy methods, Treatment Outcome, Esophageal Neoplasms, Microbiota
- Abstract
Background: The role of esophageal microbiota in esophageal cancer treatment is gaining renewed interest, largely driven by novel DNA-based microbiota analysis techniques. The aim of this systematic review is to provide an overview of current literature on the possible association between esophageal microbiota and outcome of esophageal cancer treatment, including tumor response to (neo)adjuvant chemo(radio)therapy, short-term surgery-related complications, and long-term oncological outcome., Methods: A systematic review of literature was performed, bibliographic databases were searched and relevant articles were selected by two independent researchers. The Newcastle-Ottawa scale was used to estimate the quality of included studies., Results: The search yielded 1303 articles, after selection and cross-referencing, five articles were included for qualitative synthesis and four studies were considered of good quality. Two articles addressed tumor response to neoadjuvant chemotherapy and described a correlation between high intratumoral Fusobacterium nucleatum levels and a poor response. One study assessed surgery-related complications, in which no direct association between esophageal microbiota and occurrence of complications was observed. Three studies described a correlation between shortened survival and high levels of intratumoral F. nucleatum, a low abundance of Proteobacteria and high abundances of Prevotella and Streptococcus species., Conclusions: Current evidence points towards an association between esophageal microbiota and outcome of esophageal cancer treatment and justifies further research. Whether screening of the individual esophageal microbiota can be used to identify and select patients with a predisposition for adverse outcome needs to be further investigated. This could lead to the development of microbiota-based interventions to optimize esophageal microbiota composition, thereby improving outcome of patients with esophageal cancer., (© The Author(s) 2021. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus.)
- Published
- 2022
- Full Text
- View/download PDF
33. The Thiopurine Tale: An Unexpected Journey.
- Author
-
Crouwel F, Buiter HJC, and de Boer NK
- Subjects
- Antimetabolites, Azathioprine pharmacology, Azathioprine therapeutic use, Female, Humans, Immunosuppressive Agents therapeutic use, Thioguanine therapeutic use, Inflammatory Bowel Diseases drug therapy, Mercaptopurine pharmacology, Mercaptopurine therapeutic use
- Abstract
Exactly 70 years ago [1951] mercaptopurine was discovered by Gertrude Elion as a novel treatment option for acute leukaemia. A total of three thiopurines (also thioguanine [1950] and azathioprine [1957]) were developed over time. These immunosuppressive drugs were also successfully introduced a few decades later to prevent rejection of transplanted organs and to treat several autoimmune diseases. For her discovery of thiopurines and other antimetabolite drugs, in 1988 Elion was rewarded, together with George Hitchings and James Black, with the Nobel Prize in Physiology or Medicine. Important steps have been made in recent years to unravel its metabolism, mode of action and pharmacogenetics. Today thiopurine [based] therapy remains an essential immunosuppressive approach in treating patients with inflammatory bowel disease., (© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
34. Subcutaneous administration, higher age and lower renal function are associated with erythrocyte methotrexate accumulation in Crohn's disease: a cross-sectional study.
- Author
-
van de Meeberg MM, Seinen ML, Fidder HH, Lin M, Oldenburg B, de Boer NK, Bouma G, de Jonge R, and Bulatović Ćalasan M
- Subjects
- Adult, Cross-Sectional Studies, Erythrocytes chemistry, Humans, Kidney physiology, Crohn Disease drug therapy, Methotrexate therapeutic use
- Abstract
Background: Methotrexate is an immunomodulatory drug for patients with Crohn's disease. Erythrocyte MTX-polyglutamates (MTX-PG
1-5 ) may be used for therapeutic drug monitoring (TDM) as MTX-PG is thought to mediate MTX's efficacy. Information on determinants of the concentration of MTX-PG in patients with Crohn's disease is lacking. We aim to identify clinical and biochemical determinants of the erythrocyte MTX-PG1-5 and MTX-PGtotal concentration in patients with Crohn's disease., Methods: Adults with Crohn's disease on methotrexate treatment who visited the outpatient clinic of Amsterdam UMC were included. Erythrocyte MTX-PGs were measured by tandem mass spectrometry., Results: Nineteen patients were included, with a median duration of MTX use of 77 months (range 7-202). Twelve patients received MTX monotherapy, whereas 7 patients were on concomitant TNF-α inhibitors. The mean dose of MTX was 15.5 mg (SD ± 2.8) and 12 (63%) patients used subcutaneous MTX. MTX-PG1-5 were successfully measured in 18 patients, showing substantial variability in concentrations of MTX-PGtotal and individual species. The median MTX-PGtotal was 117.1 nmol/L (range 46.4-258.7) with preferential accumulation of MTX-PG3 (43.1 nmol/L, range 15.3-96.1). Patients on subcutaneous compared to oral MTX had higher median MTX-PG(4,5) levels (55 versus 9 nmol/L, p = 0.01). Higher age (β = 0.71) and lower estimated glomerular filtration rate (β = - 0.52) were associated with a significantly higher MTX-PGtotal concentration (R2 = 0.60, p = 0.001)., Conclusion: MTX-PG concentrations display a considerable inter-individual variability. Higher MTX-PG accumulation is associated with subcutaneous administration, higher age, and lower renal function in Crohn's disease patients., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
35. The Launch of an Online National Multidisciplinary Expert Panel for Inflammatory Bowel Disease.
- Author
-
de Boer NK, van Lookeren FL, and Tack GJ
- Subjects
- Chronic Disease, Delphi Technique, Humans, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases therapy
- Published
- 2022
- Full Text
- View/download PDF
36. The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease-A Systematic Literature Review.
- Author
-
Wiersma TK, Visschedijk MC, de Boer NK, Lub-de Hooge MN, Prins JR, Touw DJ, and Mian P
- Abstract
Due to ethical and practical reasons, a knowledge gap exists on the pharmacokinetics (PK) of inflammatory bowel disease (IBD)-related drugs in pregnant women with IBD. Before evidence-based dosing can be proposed, insight into the PK has to be gained to optimize drug therapy for both mother and fetus. This systematic review aimed to describe the effect of pregnancy and IBD on the PK of drugs used for IBD. One aminosalicylate study, two thiopurine studies and twelve studies with biologicals were included. Most drugs within these groups presented data over multiple moments before, during and after pregnancy, except for mesalazine, ustekinumab and golimumab. The studies for mesalazine, ustekinumab and golimumab did not provide enough data to demonstrate an effect of pregnancy on concentration and PK parameters. Therefore, no evidence-based dosing advice was given. The 6-thioguanine nucleotide levels decreased during pregnancy to 61% compared to pre-pregnancy levels. The potentially toxic metabolite 6-methylmercaptopurine (6-MMP) increased to maximal 209% of the pre-pregnancy levels. Although the PK of the thiopurines changed throughout pregnancy, no evidence-based dosing advice was provided. One study suggested that caution should be exercised when the thiopurine dose is adjusted, due to shunting 6-MMP levels. For the biologicals, infliximab levels increased, adalimumab stayed relatively stable and vedolizumab levels tended to decrease during pregnancy. Although the PK of the biologicals changed throughout pregnancy, no evidence-based dosing advice for biologicals was provided. Other drugs retrieved from the literature search were mesalazine, ustekinumab and golimumab. We conclude that limited studies have been performed on PK parameters during pregnancy for drugs used in IBD. Therefore, more extensive research to determine the values of PK parameters is warranted. After gathering the PK data, evidence-based dosing regimens can be developed.
- Published
- 2022
- Full Text
- View/download PDF
37. Correction to: Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
- Author
-
Bayoumy AB, van Liere ELSA, Simsek M, Warner B, Loganayagam A, Sanderson JD, Anderson S, Nolan J, de Boer NK, Mulder CJJ, and Ansari A
- Published
- 2022
- Full Text
- View/download PDF
38. Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series.
- Author
-
Albshesh A, Eder P, Ribaldone DG, Oldenburg B, de Boer NK, Mantzaris GJ, Savarino EV, Dragoni G, Weisshof R, Truyens M, Festa S, Maillard MH, Capirchio L, Filip R, Theodoraki E, and Kopylov U
- Subjects
- Adult, Agammaglobulinemia epidemiology, Agammaglobulinemia therapy, Europe epidemiology, Female, Humans, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases therapy, Male, Middle Aged, Retrospective Studies, Risk Factors, Agammaglobulinemia complications, Inflammatory Bowel Diseases etiology
- Abstract
Background: Hypogammaglobulinaemia is a disorder characterized by low serum immunoglobulin levels and a high prevalence of gastrointestinal manifestations. In some cases, clinical and endoscopic features are indistinguishable from those of inflammatory bowel disease [IBD]., Methods: This was a multicentre case series performed as a part of the European Crohn's and Colitis Organisation [ECCO] Collaborative Network of Exceptionally Rare case reports [CONFER] project., Results: This report includes 27 patients with primary hypogammaglobulinaemia and IBD-like features: 20 males and seven females, median age 45.6 years (interquartile range [IQR] 35.2-59). Crohn's disease-like features were noted in 23 patients, and four patients had ulcerative colitis-like features. The diagnosis of hypogammaglobulinaemia preceded a diagnosis of IBD-like features in 20 patients [median of 7 years prior, IQR 2.6-20.6 years], and followed the appearance of IBD-like features in seven cases [median of 1 year after, IQR 0.45-5.6 years]. Hypogammaglobulinaemia aetiologies were common variable immunodeficiency [66.6%], agammaglobulinaemia [7.4%], selective IgA-deficiency [11.1%], Good's syndrome [7.4%], IgG subclass deficiency with IgA deficiency [3.7%] and hyper-IgM [3.7%]. In addition to antibiotics and intravenous immunoglobulin [IVIG] for hypogammaglobulinaemia, 12 patients received IBD-related treatment including 5-aminosalicylate agents [two patients], corticosteroids [one patient], thiopurines [three patients], anti-tumour necrosis factor [four patients] and vedolizumab [two patients]. By the end of the follow-up (44.5 months [IQR 18-81]), 21/27 [77%] patients were in clinical remission., Conclusion: This case series describes IBD-like features in patients with hypogammaglobulinaemia. The diagnosis of IBD-like features mainly occurred after that of hypogammaglobulinaemia, with successful recovery in the majority of cases after appropriate treatment., (© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
39. The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma.
- Author
-
Bosch S, Acharjee A, Quraishi MN, Rojas P, Bakkali A, Jansen EE, Brizzio Brentar M, Kuijvenhoven J, Stokkers P, Struys E, Beggs AD, Gkoutos GV, de Meij TG, and de Boer NK
- Subjects
- Amino Acids, Case-Control Studies, Humans, Risk Factors, Adenoma diagnosis, Adenoma pathology, Colorectal Neoplasms pathology, Gastrointestinal Microbiome
- Abstract
The risk of recurrent dysplastic colonic lesions is increased following polypectomy. Yield of endoscopic surveillance after adenoma removal is low, while interval colorectal cancers occur. To longitudinally assess the dynamics of fecal microbiota and amino acids in the presence of adenomatous lesions and after their endoscopic removal. In this longitudinal case-control study, patients collected fecal samples prior to bowel preparation before scheduled colonoscopy and 3 months after this intervention. Based on colonoscopy outcomes, patients with advanced adenomas and nonadvanced adenomas (0.5-1.0 cm) who underwent polypectomy during endoscopy ( n = 19) were strictly matched on age, body-mass index, and smoking habits to controls without endoscopic abnormalities ( n = 19). Microbial taxa were measured by 16S RNA sequencing, and amino acids (AA) were measured by high-performance liquid chromatography (HPLC). Adenoma patients were discriminated from controls based on AA and microbial composition. Levels of proline ( p = .001), ornithine ( p = .02) and serine ( p = .02) were increased in adenoma patients compared to controls but decreased to resemble those of controls after adenoma removal. These AAs were combined as a potential adenoma-specific panel (AUC 0.79(0.64-0.94)). For bacterial taxa, differences between patients with adenomas and controls were found ( Bifidobacterium spp.↓, Anaerostipes spp.↓, Butyricimonas spp.↑, Faecalitalea spp.↑ and Catenibacterium spp.↑), but no alterations in relative abundance were observed after polypectomy. Furthermore, Faecalitalea spp. and Butyricimonas spp. were significantly correlated with adenoma-specific amino acids. We selected an amino acid panel specifically increased in the presence of adenomas and a microbial signature present in adenoma patients, irrespective of polypectomy. Upon validation, these panels may improve the effectiveness of the surveillance program by detection of high-risk individuals and determination of surveillance endoscopy timing, leading to less unnecessary endoscopies and less interval cancer.
- Published
- 2022
- Full Text
- View/download PDF
40. Integration of stool microbiota, proteome and amino acid profiles to discriminate patients with adenomas and colorectal cancer.
- Author
-
Bosch S, Acharjee A, Quraishi MN, Bijnsdorp IV, Rojas P, Bakkali A, Jansen EE, Stokkers P, Kuijvenhoven J, Pham TV, Beggs AD, Jimenez CR, Struys EA, Gkoutos GV, de Meij TG, and de Boer NK
- Subjects
- Humans, Proteome analysis, Chromatography, Liquid, RNA, Ribosomal, 16S, Amino Acids, Tandem Mass Spectrometry, Feces chemistry, Colorectal Neoplasms diagnosis, Colorectal Neoplasms genetics, Gastrointestinal Microbiome, Adenoma diagnosis
- Abstract
Background: Screening for colorectal cancer (CRC) reduces its mortality but has limited sensitivity and specificity. Aims We aimed to explore potential biomarker panels for CRC and adenoma detection and to gain insight into the interaction between gut microbiota and human metabolism in the presence of these lesions., Methods: This multicenter case-control cohort was performed between February 2016 and November 2019. Consecutive patients ≥18 years with a scheduled colonoscopy were asked to participate and divided into three age, gender, body-mass index and smoking status-matched subgroups: CRC (n = 12), adenomas (n = 21) and controls (n = 20). Participants collected fecal samples prior to bowel preparation on which proteome (LC-MS/MS), microbiota (16S rRNA profiling) and amino acid (HPLC) composition were assessed. Best predictive markers were combined to create diagnostic biomarker panels. Pearson correlation-based analysis on selected markers was performed to create networks of all platforms., Results: Combining omics platforms provided new panels which outperformed hemoglobin in this cohort, currently used for screening (AUC 0.98, 0.95 and 0.87 for CRC vs controls, adenoma vs controls and CRC vs adenoma, respectively). Integration of data sets revealed markers associated with increased blood excretion, stress- and inflammatory responses and pointed toward downregulation of epithelial integrity., Conclusions: Integrating fecal microbiota, proteome and amino acids platforms provides for new biomarker panels that may improve noninvasive screening for adenomas and CRC, and may subsequently lead to lower incidence and mortality of colon cancer.
- Published
- 2022
- Full Text
- View/download PDF
41. Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study.
- Author
-
Goetgebuer RL, Kreijne JE, Aitken CA, Dijkstra G, Hoentjen F, de Boer NK, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Pierik MJ, van Kemenade FJ, de Kok IMCM, Siebers AG, Manniën J, van der Woude CJ, and de Vries AC
- Subjects
- Adult, Aged, Case-Control Studies, Cohort Studies, Early Detection of Cancer, Female, Humans, Immunosuppressive Agents therapeutic use, Incidence, Inflammatory Bowel Diseases pathology, Middle Aged, Neoplasm Grading, Netherlands, Papanicolaou Test, Patient Compliance, Risk Factors, Inflammatory Bowel Diseases complications, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Dysplasia diagnosis, Uterine Cervical Dysplasia epidemiology
- Abstract
Background and Aims: Women with inflammatory bowel disease [IBD] may be at higher risk for cervical intraepithelial neoplasia [CIN]. However, data are conflicting. The aim of this study was to assess the risk of high-grade dysplasia and cancer [CIN2+] in IBD women and identify risk factors., Methods: Clinical data from adult IBD women in a multicentre Dutch IBD prospective cohort [PSI] from 2007 onwards were linked to cervical cytology and histology records from the Dutch nationwide cytology and pathology database [PALGA], from 2000 to 2016. Patients were frequency-matched 1:4 to a general population cohort. Standardised detection rates [SDR] were calculated for CIN2+. Longitudinal data were assessed to calculate CIN2+ risk during follow-up using incidence rate ratios [IRR] and risk factors were identified in multivariable analysis., Results: Cervical records were available from 2098 IBD women [77%] and 8379 in the matched cohort; median follow-up was 13 years. CIN2+ detection rate was higher in the IBD cohort than in the matched cohort (SDR 1.27, 95% confidence interval [CI] 1.05-1.52). Women with IBD had an increased risk of CIN2+ [IRR 1.66, 95% CI 1.21-2.25] and persistent or recurrent CIN during follow-up (odds ratio [OR] 1.89, 95% CI 1.06-3.38). Risk factors for CIN2+ in IBD women were smoking and disease location (ileocolonic [L3] or upper gastrointestinal [GI] [L4]). CIN2+ risk was not associated with exposure to immunosuppressants., Conclusions: Women with IBD are at increased risk for CIN2+ lesions. These results underline the importance of human papillomavirus [HPV] vaccination and adherence to cervical cancer screening guidelines in IBD women, regardless of exposure to immunosuppressants., (© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.)
- Published
- 2021
- Full Text
- View/download PDF
42. Azathioprine-induced Myelotoxicity After Switching Mesalazine Compound.
- Author
-
Barnhoorn MC, Storm BN, de Boer NK, and van der Voorn MMPJA
- Subjects
- Drug Substitution, Humans, Mesalamine, Azathioprine adverse effects, Immunosuppressive Agents adverse effects, Inflammatory Bowel Diseases drug therapy
- Published
- 2021
- Full Text
- View/download PDF
43. Hypnotherapy for Irritable Bowel Syndrome-Type Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Controlled Trial.
- Author
-
Hoekman DR, Vlieger AM, Stokkers PC, Mahhmod N, Rietdijk S, de Boer NK, de Meij TG, Frankenhuis C, D'Haens GR, and Benninga MA
- Subjects
- Adolescent, Adult, Aged, Biomarkers analysis, Child, Female, Humans, Male, Middle Aged, Netherlands, Quality of Life, Hypnosis, Irritable Bowel Syndrome therapy
- Abstract
Background and Aims: Many inflammatory bowel disease [IBD] patients in remission have persisting symptoms, compatible with irritable bowel syndrome [IBS-type symptoms]. We aimed to compare the effectiveness of gut-directed hypnotherapy vs standard medical treatment [SMT] for IBS-type symptoms in IBD patients., Methods: In this multicentre, randomized, controlled, open-label trial, patients aged 12-65 years with IBD in clinical remission [global assessment] and biochemical remission [faecal calprotectin ≤100 µg/g, or ≤200 µg/g without inflammation at endoscopy] with IBS according to Rome III criteria were randomized to hypnotherapy or SMT. Primary outcome was the proportion with ≥50% reduction on a visual analog scale for symptom severity, as measured with the Irritable Bowel Syndrome Severity Scoring System [IBS-SSS] at week 40 [i.e. 6 months after finishing the intervention], compared to baseline. Secondary outcomes included total IBS-SSS score, quality of life, adequate relief, IBS-related cognitions, and depression and anxiety scores., Results: Eighty patients were included, of whom 70 received at least one session of the allocated treatment and were included in the modified intention-to-treat-population. Seven patients were excluded because of missing baseline data required for the primary outcome. The primary outcome was met in nine [27%] of 33 patients randomized to SMT and nine [30%] of 30 patients randomized to hypnotherapy [p = 0.81]. Adequate relief was reported in 60% and 40% of subjects, respectively. Exploratory analyses of secondary outcomes revealed no apparent differences between the two treatment groups., Conclusions: Hypnotherapy was not superior to SMT in the treatment of IBS-type symptoms in IBD patients. Both treatment strategies are reasonable options from a clinical perspective., (© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.)
- Published
- 2021
- Full Text
- View/download PDF
44. Recurrent COVID-19 in a Patient With Ulcerative Colitis on Vedolizumab Therapy.
- Author
-
Crouwel F, Waaijenberg-Warmenhoven P, Buiter HJC, and de Boer NK
- Subjects
- Adult, Colitis, Ulcerative complications, Female, Humans, Reinfection diagnosis, Antibodies, Monoclonal, Humanized therapeutic use, COVID-19 diagnosis, COVID-19 etiology, Colitis, Ulcerative therapy, Gastrointestinal Agents therapeutic use, Reinfection etiology
- Published
- 2021
- Full Text
- View/download PDF
45. Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease: A Nationwide Cohort Study.
- Author
-
Beelen EMJ, van der Woude CJ, Pierik MJ, Hoentjen F, de Boer NK, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Dijkstra G, Bruggink AH, Erler NS, Schouten WR, and de Vries AC
- Subjects
- Adult, Cohort Studies, Female, Humans, Male, Netherlands, Registries, Colorectal Surgery trends, Crohn Disease surgery, Practice Patterns, Physicians' trends
- Abstract
Objective: To assess time trends in intestinal resection and re-resection in Crohn's disease (CD) patients., Summary of Background Data: CD treatment has changed considerably over the past decades. The effect of these advances on the necessity of intestinal resections and the risk of re-resection is unclear., Methods: In this nationwide cohort study, adult CD patients with ileocolonic, small bowel, colon, or rectum resections between 1991 and 2015 were included. Data were retrieved from the Dutch nationwide network and registry of histopathology and cytopathology (PALGA). Time trends were analyzed with a broken stick model and Cox proportional hazard model with smoothing splines., Results: The identified cohort comprised 8172 CD patients (3293/4879 male/female) in whom 10,315 intestinal resections were performed. The annual intestinal resection rate decreased nonlinearly from 1.9/100,000 (1991) to 0.2/100,000 (2015). A significantly steeper-decrease was observed before 1999 (slope –0.13) as compared to subsequent years (slope –0.03) (p<0.001). Analogous trends were observed for ileocolonic, small bowel, and colon resections. Overall cumulative risk of re-resection was 10.9% at 5 years, 18.6% at 10 years, and 28.3% at 20 years after intestinal resection. The hazard for intestinal re-resection showed a nonlinear decreasing trend, with hazard ratio 0.39 (95% confidence interval 0.36-0.44) in 2000 and hazard ratio 0.25 (95% confidence interval 0.18-0.34) in 2015 as compared to 1991., Conclusion: Over the past 25 years, intestinal resection rate has decreased significantly for ileocolonic, small bowel, and colonic CD. In addition, current postoperative CD patients are at 75% lower risk of intestinal re-resection., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2021
- Full Text
- View/download PDF
46. Cutaneous Metastasis From a Laryngeal Carcinoma After Push Method Percutaneous Endoscopic Gastrostomy.
- Author
-
Hoogenes N, Daams F, Britstra R, Nielsen K, de Boer NK, and Hendrickx JJ
- Subjects
- Aged, Female, Humans, Neoplasm Seeding, Gastroscopy methods, Gastrostomy methods, Laryngeal Neoplasms pathology, Skin Neoplasms secondary, Squamous Cell Carcinoma of Head and Neck secondary
- Published
- 2021
- Full Text
- View/download PDF
47. Thioguanine Therapy in Inflammatory Bowel Diseases. A Practical Guide.
- Author
-
Crouwel F, Simsek M, Mulder CJ, Buiter HJ, and De Boer NK
- Subjects
- Humans, Immunosuppressive Agents therapeutic use, Inflammatory Bowel Diseases drug therapy, Thioguanine therapeutic use
- Abstract
Thiopurine-derivates azathioprine and mercaptopurine are frequently used to maintain remission in inflammatory bowel diseases (IBD). Despite their efficacy, more than 50% of patients discontinue therapy, mainly due to the development of adverse events. Thioguanine is an alternative thiopurine and has been conditionally licensed in The Netherlands as IBD treatment for patients after conventional thiopurine therapy failure. In this review we will provide practical information on initiating and maintaining thioguanine therapy in IBD and provide information concerning safety issues and future perspectives. The thioguanine toxicity profile is relatively mild and the reported incidence of nodular regenerative hyperplasia related to thioguanine use seems comparable to conventional thiopurines and the background incidence in IBD patients. Routine monitoring of laboratory parameters and adverse events is recommended, comparable to the monitoring of patients on conventional thiopurine therapy.
- Published
- 2020
- Full Text
- View/download PDF
48. Discontinuation rate of azathioprine.
- Author
-
Crouwel F, Buiter HJC, and de Boer NK
- Subjects
- Azathioprine adverse effects, Humans, Immunosuppressive Agents, Crohn Disease, Hepatitis, Autoimmune
- Published
- 2020
- Full Text
- View/download PDF
49. Oral health and salivary function in ulcerative colitis patients.
- Author
-
Goldinova A, Tan CX, Bouma G, Duijvestein M, Brand HS, and de Boer NK
- Subjects
- Adolescent, Adult, Aged, Colitis, Ulcerative diagnosis, Colitis, Ulcerative immunology, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Quality of Life, Salivary Glands immunology, Self Report statistics & numerical data, Severity of Illness Index, Xerostomia immunology, Xerostomia physiopathology, Young Adult, Colitis, Ulcerative complications, Oral Health, Salivary Glands physiopathology, Salivation immunology, Xerostomia diagnosis
- Abstract
Background: Although ulcerative colitis primarily involves the colon, extra-intestinal manifestations are common and oral and dental complaints are no exception., Objective: This study aims at evaluating oral and dental health problems and salivary function and composition in ulcerative colitis patients and its correlation with disease activity., Methods: Xerostomia Inventory score, (unstimulated/stimulated) salivary flow rates, salivary amylase and mucin/ Mucin 5B levels, self-reported oral and dental complaints, the oral health related quality of life, Simple Clinical Colitis Activity Index and inflammatory bowel disease-specific health related quality of life were determined., Results: The cohort consisted of 51 ulcerative colitis patients. Hyposalivation was experienced by 16% of patients under resting conditions and 24% under chewing-stimulated conditions. Xerostomia was not correlated with salivary flow rates. Disease activity did not influence salivary amylase and Mucin 5B concentrations. The Xerostomia Inventory score was correlated with the Simple Clinical Colitis Activity Index ( p = 0.042) and inflammatory bowel disease-specific health related quality of life ( p = 0.001). Most reported oral health problems were halitosis (29%) and aphthae (28%). Frequently reported dental problems were cavities (35%) and gum problems (31%). Patients with active disease experienced significantly more oral and dental complaints. The number of oral problems was positively correlated with the Simple Clinical Colitis Activity Index ( p = 0.045) and negatively correlated with the inflammatory bowel disease-specific health related quality of life ( p = 0.005)., Conclusion: The subjective feeling of a dry mouth (xerostomia) is related to disease activity and disease activity-associated quality of life in ulcerative colitis patients, whereas the objective saliva secretion rate is not. Oral and dental health problems are frequently observed in patients with ulcerative colitis, especially during active disease.
- Published
- 2020
- Full Text
- View/download PDF
50. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
- Author
-
Bayoumy AB, van Liere ELSA, Simsek M, Warner B, Loganayagam A, Sanderson JD, Anderson S, Nolan J, de Boer NK, Mulder CJJ, and Ansari A
- Subjects
- Azathioprine adverse effects, Female, Humans, Immunosuppressive Agents adverse effects, Male, Mercaptopurine, Retrospective Studies, Thioguanine adverse effects, Treatment Outcome, United Kingdom, Inflammatory Bowel Diseases drug therapy, Pharmaceutical Preparations
- Abstract
Background: Thioguanine (TG) is a thiopurine which has been used for patients with inflammatory bowel disease (IBD), who have failed azathioprine (AZA) or mercaptopurine (MP) due to adverse events or suboptimal response. Its widespread use has been hampered due to concerns about nodular regenerative hyperplasia (NRH) of the liver. The aim of this study was to investigate the long-term efficacy and safety of low-dose TG therapy in IBD patients failing AZA and MP., Methods: A retrospective multicentre study was performed in IBD patients who failed prior treatment with conventional thiopurines with or without following immunomodulation (thiopurine-allopurinol, biologicals, methotrexate, tacrolimus) and were subsequently treated with TG as rescue monotherapy between 2003 and 2019 at three hospitals in the United Kingdom. Clinical response, adverse events, laboratory results, imaging and liver biopsies were retrospectively collected., Results: A total of 193 patients (57% female and 64% Crohn's disease) were included, with a median daily TG dose of 20 mg (range: 20-40 mg), a median treatment duration of 23 months (IQR 10-47) and a median follow-up of 36 months (IQR 22-53). The clinical response rate at 12 months was 65 and 54% remained on TG until the end of follow-up. Adverse events consisted primarily of elevated liver tests (6%), myelotoxicity (7%) and rash (5%). NRH was histologically diagnosed in two patients and two other patients (1%) developed non-cirrhotic portal hypertension. The median 6-TGN and TPMT levels were 953 pmol/8 × 10
5 RBC (IQR 145-1761) and 47 mu/L (IQR 34.5-96)., Conclusions: Long-term follow-up suggests that TG can be an effective and well-tolerated therapy in more than half of difficult-to-treat and multi-therapy failing IBD patients. Findings of this study indicate that TG can be used safely and the occurrence of hepatotoxicity was low. The incidence rate of NRH was within the background incidence.- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.